Other Information
−Removed: Securities Trading Plans of Directors and Executive Officers
−Removed: On February 20, 2026 , Evert Schimmelpennink , our Chief Executive Officer , terminated a previously disclosed 10b5-1 trading plan that was intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and was adopted on August 11, 2025.
−Removed: The 10b5-1 trading plan provided for the sale of up to 225,000 shares of the Company’s common stock related to the exercise of option awards granted to Mr.
−Removed: Schimmelpennink.
−Removed: No shares were sold under the plan prior to its termination.
−Removed: During our last fiscal quarter, none of our other directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.
+Added: During our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.
3.1 Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024).
1 unchanged sentence
4.1 Form of Warrant to Purchase Shares of Series A Preferred Stock (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-4 filed with the SEC on December 6, 2023).
+Added: 10.1* O utside Director Compensation Policy
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
12 unchanged sentences
__________________
+Added: * Filed herewith.
** The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the SEC and are not to be incorporated by reference into any filing of LENZ Therapeutics, Inc.
2 unchanged sentences
LENZ THERAPEUTICS, INC.
+Added: August 11, 2026
/s/ Evert Schimmelpennink
2 unchanged sentences
(Principal Executive Officer)
+Added: August 11, 2026
/s/ Daniel Chevallard
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.